TOKYO, Apr 30 (Pulse News Wire) – North Ridge Corporation (368A.T) reported its consolidated performance for the fiscal year ended March 31, 2026, surpassing previous forecasts released on June 25, 2025. Revenue reached ¥14.89 billion, up from the earlier estimate of ¥14.546 billion, while operating profit was ¥5.374 billion compared to the forecast of ¥5.267 billion.
The company attributed the positive results to strong demand for infertility treatment products domestically and internationally, particularly in Europe and India. Increased sales led to higher gross profits, which combined with cost management efforts, resulted in improved operating income.
Additionally, foreign exchange gains due to a weakening yen contributed significantly to the better-than-expected net income. For the fiscal year, the company's earnings per share stood at ¥146, marking an increase from the previously estimated ¥138.
Overall, the firm saw improvements across key metrics, including a 12.1% rise in ordinary profit and an 11.3% boost in net profit attributable to parent shareholders.
🟢 Confidence: High AI-translated content.